BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of investors of CytRx Corporation (“CytRx” or the “Company”) (NASDAQ: CYTR) concerning the Company and its officers’ possible violations of federal securities laws.
CytRx is a biopharmaceutical research and development company that specializes in oncology.
On July 11, 2016, CytRx released the results of its Phase 3 clinical trial of aldoxorubicin, a product candidate designed for patients with soft tissues sarcomas (“STS”), which did not show noticeable improvement over other widely used cancer drugs. Additionally, the Company announced that nearly half of the patients in the Phase 3 trial were excluded from the data due to a partial clinical hold back in November 2014. Following this disclosure, shares of CytRx were down over 63% during intraday trading on July 12, 2016.
If you purchased CytRx securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to firstname.lastname@example.org, or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.